Kyverna Therapeutics (NasdaqGS:KYTX) 2026 Conference Transcript

Kyverna Therapeutics Conference Call Summary Company Overview - Company: Kyverna Therapeutics (NasdaqGS:KYTX) - Focus: Development of autologous CAR T therapies, specifically targeting rare autoimmune diseases Key Highlights from 2025 and Early 2026 - Positive Results: Kyverna reported positive top-line results from pivotal studies for miv-cel, an autologous CD19 CAR T therapy for stiff person syndrome, indicating a transformative period ahead in 2026 with a BLA submission expected in the first half of the year [3][5] - Unique Construct: Miv-cel is a second-generation CAR T therapy designed for improved potency, efficacy, and safety, with a tenfold reduction in high-grade CRS and ICANS compared to traditional CAR Ts [4][10] Stiff Person Syndrome (SPS) - Unmet Need: SPS has no FDA-approved therapies, with 80% of patients progressing to severe disability, highlighting a significant unmet medical need [12] - Clinical Impact: Miv-cel demonstrated a 46% reduction in the timed 25-foot walk test by the 16-week primary endpoint, significantly exceeding the clinically meaningful response threshold of 20% [14][15] - BLA Filing: Kyverna is on track to file for BLA approval by the end of 2026, potentially becoming the first autologous CAR T therapy approved for autoimmune diseases [13][21] Regulatory and Manufacturing Insights - FDA Engagement: Continuous positive interactions with the FDA, including RMAT and orphan drug designations, provide confidence in the approval pathway [21] - Manufacturing Success: A 95% manufacturing success rate has been achieved in clinical trials, with plans to scale up for launch [22][55] Commercial Strategy - Target Patient Population: Approximately 6,000 patients in the U.S. with SPS, with 2,000-2,500 being refractory to existing treatments, representing the initial target market [27] - Pricing Strategy: Kyverna plans to justify a premium pricing model based on the health economic burden of SPS and the potential to eliminate chronic therapies [25][26] Myasthenia Gravis (MG) Development - Next Indication: Myasthenia gravis is viewed as a valuable market opportunity, with a significant patient population of 80,000, of which 12,000-13,000 are refractory to existing therapies [48] - Pivotal Phase 3 Study: Actively enrolling patients with a unique randomized design to compare miv-cel against standard care, aiming for superiority in clinical outcomes [45][46] Pipeline and Future Opportunities - Neuroimmunology Franchise: Kyverna is building a portfolio beyond SPS and MG, with promising early data in progressive MS showing significant improvements in patient outcomes [57][58] - KYV-102 Development: A next-generation manufacturing process that utilizes whole blood, improving patient access and reducing costs, is in the IND submission stage [59][61] Conclusion - Kyverna Therapeutics is positioned for a transformative year in 2026 with significant advancements in its CAR T therapies for rare autoimmune diseases, a strong regulatory pathway, and a focused commercial strategy targeting high unmet needs in SPS and MG [3][5][21]